| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/CIRCRESAHA.113.300752 |
| P8608 | Fatcat ID | release_rfl3ugqmnrfwjd2mgven4lfehe |
| P3181 | OpenCitations bibliographic resource ID | 230468 |
| P932 | PMC publication ID | 4131731 |
| P698 | PubMed publication ID | 23788505 |
| P2093 | author name string | Y. Xia | |
| R. E. Kellems | |||
| P2860 | cites work | Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 |
| Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression | Q28573546 | ||
| Potential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertension | Q28575913 | ||
| Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis | Q28589061 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia | Q33591058 | ||
| Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia | Q33748650 | ||
| Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity | Q33748680 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Agonist-like beta-adrenoceptor antibodies in heart failure | Q33883087 | ||
| Fetal nutrition and adult disease | Q33900856 | ||
| Pathogenesis and genetics of pre-eclampsia | Q33934445 | ||
| Angiotensin receptor agonistic autoantibody-mediated soluble fms-like tyrosine kinase-1 induction contributes to impaired adrenal vasculature and decreased aldosterone production in preeclampsia | Q34040304 | ||
| Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia | Q34040357 | ||
| The angiotensin II AT2 receptor is an AT1 receptor antagonist. | Q34086986 | ||
| Post-translational protein modifications in antigen recognition and autoimmunity | Q34319948 | ||
| Inflammation, immunity, and hypertension | Q34528283 | ||
| Posttranslational protein modifications: new flavors in the menu of autoantigens | Q34618160 | ||
| beta(1)-Adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. | Q34651493 | ||
| Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia | Q34785813 | ||
| Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes | Q35029700 | ||
| Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia | Q35079406 | ||
| CD4+ T-helper cells stimulated in response to placental ischemia mediate hypertension during pregnancy | Q35130793 | ||
| Angiotensin II type 1 autoantibody induced hypertension during pregnancy is associated with renal endothelial dysfunction | Q35576417 | ||
| Dimerization of G-protein-coupled receptors: roles in signal transduction | Q35592680 | ||
| Roles of G-protein-coupled receptor dimerization | Q35622424 | ||
| G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling | Q35625502 | ||
| Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling | Q35681804 | ||
| Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice | Q35683468 | ||
| Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice | Q35701236 | ||
| Receptor-activating autoantibodies and disease: preeclampsia and beyond | Q35707881 | ||
| Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia | Q35715914 | ||
| Renin angiotensin signaling in normal pregnancy and preeclampsia | Q35743816 | ||
| Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats | Q35994304 | ||
| Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling | Q36050771 | ||
| Is preeclampsia an autoimmune disease? | Q36050775 | ||
| A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model | Q36115311 | ||
| IL-17-mediated oxidative stress is an important stimulator of AT1-AA and hypertension during pregnancy | Q36178540 | ||
| Posttranslational modifications of self-antigens | Q36193038 | ||
| Hypertension in response to IL-6 during pregnancy: role of AT1-receptor activation | Q36244980 | ||
| Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications | Q36245112 | ||
| Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia | Q36355165 | ||
| The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy | Q36407259 | ||
| Angiogenic factors in preeclampsia and related disorders | Q36526596 | ||
| TSH receptor antibodies | Q36953687 | ||
| Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction | Q37022723 | ||
| The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia | Q37088970 | ||
| Pathophysiology of hypertension in response to placental ischemia during pregnancy: a central role for endothelin? | Q37131819 | ||
| Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats | Q37436219 | ||
| Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. | Q37447371 | ||
| Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade | Q37459545 | ||
| Pathogenesis of preeclampsia | Q37676212 | ||
| Autoantigenesis: the evolution of protein modifications in autoimmune disease | Q37972473 | ||
| Role of non-HLA antibodies in organ transplantation | Q38025851 | ||
| Non-HLA-antibodies targeting Angiotensin type 1 receptor and antibody mediated rejection | Q38028216 | ||
| Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies | Q38494999 | ||
| Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. | Q43576536 | ||
| Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension | Q44162378 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
| AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 | ||
| Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection | Q45259438 | ||
| From agonist to antagonist: Fab fragments of an agonist-like monoclonal anti-beta(2)-adrenoceptor antibody behave as antagonists | Q46208108 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 | ||
| Complement activation in angiotensin II-induced organ damage | Q46658434 | ||
| Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness | Q46841539 | ||
| Thyroid-stimulating immunoglobulins in Graves' disease | Q46966821 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. | Q51139503 | ||
| Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. | Q52886517 | ||
| Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. | Q52900457 | ||
| Is parvovirus B19 the cause for autoimmunity against the angiotensin II type receptor? | Q52928690 | ||
| Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. | Q52940276 | ||
| Correlation between HLA-DRB1, HLA-DQB1 polymorphism and autoantibodies against angiotensin AT(1) receptors in Chinese patients with essential hypertension. | Q54373900 | ||
| Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. | Q54782424 | ||
| Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension | Q71662795 | ||
| Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen | Q71695937 | ||
| Agonistic effects of anti-peptide antibodies and autoantibodies directed against adrenergic and cholinergic receptors: absence of desensitization | Q71917946 | ||
| Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect | Q72523353 | ||
| Alpha 1-adrenergic receptor antibodies in patients with primary hypertension | Q73089177 | ||
| Fetal origins of cardiovascular disease | Q73134554 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension | Q74126541 | ||
| Autoantibodies against M2 muscarinic receptors in patients with cardiomyopathy display non-desensitized agonist-like effects | Q74589807 | ||
| In utero programming of chronic disease | Q74813945 | ||
| Functional and structural characterization of anti-beta1-adrenoceptor autoantibodies of spontaneously hypertensive rats | Q79201165 | ||
| Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia | Q82705098 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | arterial hypertension | Q41861 |
| pre-eclampsia | Q61335 | ||
| autoantibody | Q785022 | ||
| P304 | page(s) | 78-87 | |
| P577 | publication date | 2013-06-21 | |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond | |
| P478 | volume | 113 |
| Q54361188 | A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia. |
| Q53700889 | AT1-AA (Angiotensin II Type 1 Receptor Agonistic Autoantibody) Blockade Prevents Preeclamptic Symptoms in Placental Ischemic Rats. |
| Q36052778 | AT2R autoantibodies block angiotensin II and AT1R autoantibody-induced vasoconstriction |
| Q34541831 | Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor Enhance Angiotensin II-Induced Renal Vascular Sensitivity and Reduce Renal Function During Pregnancy |
| Q89006965 | Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology |
| Q26779600 | Angiotensin Receptors: Structure, Function, Signaling and Clinical Applications |
| Q92594858 | Angiotensin receptor autoantibodies as exposures that modify disease progression: Cross sectional, longitudinal and in vitro studies of prostate cancer |
| Q26828588 | Antibodies in the pathogenesis of hypertension |
| Q37000033 | Apoptotic and stress signaling markers are augmented in preeclamptic placenta and umbilical cord |
| Q41325907 | Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer's Disease |
| Q107324240 | Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19 |
| Q90599535 | Autoantibodies against AT1 Receptor Contribute to Vascular Aging and Endothelial Cell Senescence |
| Q50077615 | Autoantibodies against angiotensin and adrenergic receptors: more than a biomarker? |
| Q52603631 | Autoantibodies in Serum of Systemic Scleroderma Patients: Peptide-Based Epitope Mapping Indicates Increased Binding to Cytoplasmic Domains of CXCR3. |
| Q40153619 | Autoantibody profiling on a plasmonic nano-gold chip for the early detection of hypertensive heart disease. |
| Q35116086 | Autoimmunity: an underlying factor in the pathogenesis of hypertension |
| Q38891100 | Clinical value of non-HLA antibodies in kidney transplantation: Still an enigma? |
| Q48662976 | Complement activation, a threat to pregnancy |
| Q51464431 | Complement component C1q as potential diagnostic but not predictive marker of preeclampsia. |
| Q38430192 | Consensus strategy in genes prioritization and combined bioinformatics analysis for preeclampsia pathogenesis |
| Q93109012 | Disturbed Cardiorespiratory Adaptation in Preeclampsia: Return to Normal Stress Regulation Shortly after Delivery? |
| Q91813359 | Early-Onset Preeclampsia Is Associated With Gut Microbial Alterations in Antepartum and Postpartum Women |
| Q36575544 | Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia |
| Q37642331 | Endothelial Cells in Antibody-Mediated Rejection of Kidney Transplantation: Pathogenesis Mechanisms and Therapeutic Implications. |
| Q46303776 | Ferulic acid alleviates symptoms of preeclampsia in rats by upregulating vascular endothelial growth factor. |
| Q35983558 | Hypertension and immunity: mechanisms of T cell activation and pathways of hypertension |
| Q36879266 | Hypoxia-independent upregulation of placental hypoxia inducible factor-1α gene expression contributes to the pathogenesis of preeclampsia |
| Q53433801 | Identification of a Novel Agonist-Like Autoantibody in Preeclamptic Patients. |
| Q37139722 | Identifying immune mechanisms mediating the hypertension during preeclampsia |
| Q38789230 | Impact of Immune Deficiency on Remodeling of Maternal Resistance Vasculature 4 Weeks Postpartum in Mice |
| Q96230486 | Increased AT2R expression is induced by AT1R autoantibody via two axes, Klf-5/IRF-1 and circErbB4/miR-29a-5p, to promote VSMC migration |
| Q37605722 | Increased risk of systemic lupus erythematosus in pregnancy-induced hypertension: A nationwide population-based retrospective cohort study |
| Q39198610 | Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase |
| Q36241932 | International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. |
| Q48160896 | Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study. |
| Q55004295 | Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study. |
| Q35175458 | Novel retro-inverso peptide inhibitor reverses angiotensin receptor autoantibody-induced hypertension in the rabbit |
| Q39294794 | Pathogenesis of systemic sclerosis-current concept and emerging treatments |
| Q39208841 | Pharmacogenetics in the treatment of pre-eclampsia: current findings, challenges and perspectives |
| Q37451544 | Placental Ischemia and Resultant Phenotype in Animal Models of Preeclampsia |
| Q47841212 | Pre-Eclampsia and Eclampsia: An Update on the Pharmacological Treatment Applied in Portugal |
| Q33416340 | Pre-eclampsia part 1: current understanding of its pathophysiology |
| Q26746841 | Pre-eclampsia: its pathogenesis and pathophysiolgy |
| Q91815900 | Pre-eclampsia: pathogenesis, novel diagnostics and therapies |
| Q38889590 | Preeclampsia and the brain: neural control of cardiovascular changes during pregnancy and neurological outcomes of preeclampsia |
| Q26800272 | Preeclampsia: long-term consequences for vascular health |
| Q90704817 | Preformed Angiotensin II Type-1 Receptor Antibodies Are Associated With Rejection After Kidney Transplantation: A Single-Center, Cohort Study |
| Q36556973 | Preparation and Biological Activity of the Monoclonal Antibody against the Second Extracellular Loop of the Angiotensin II Type 1 Receptor |
| Q92071252 | Renal natural killer cell activation and mitochondrial oxidative stress; new mechanisms in AT1-AA mediated hypertensive pregnancy |
| Q37067705 | Role of agonistic autoantibodies against type-1 angiotensin II receptor in the pathogenesis of retinopathy in preeclampsia |
| Q36496133 | Role of immune cells in salt-sensitive hypertension and renal injury |
| Q39342382 | Role of the Immune System in Hypertension |
| Q35592165 | Structure of the Angiotensin receptor revealed by serial femtosecond crystallography. |
| Q50055232 | Successful Treatment of Anti-angiotensin II Type 1 Receptor Antibody-Associated Rejection in Kidney Transplantation: A Case Report |
| Q51249136 | The effects of sildenafil citrate on urinary podocin and nephrin mRNA expression in an L-NAME model of pre-eclampsia. |
| Q34683745 | The immunological basis of hypertension |
| Q38877375 | The importance of non-HLA antibodies in transplantation |
| Q27003301 | The renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin? |
| Q37240779 | Transglutaminase is a Critical Link Between Inflammation and Hypertension |
Search more.